239 related articles for article (PubMed ID: 31431377)
1. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.
Jackson WC; Suresh K; Maurino C; Feng M; Cuneo KC; Ten Haken RK; Lawrence TS; Schipper MJ; Owen D
Radiother Oncol; 2019 Dec; 141():101-107. PubMed ID: 31431377
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
3. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
4. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
[TBL] [Abstract][Full Text] [Related]
6. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease.
Jackson WC; Tang M; Maurino C; Mendiratta-Lala M; Parikh ND; Matuszak MM; Dow JS; Cao Y; Mayo CS; Ten Haken RK; Schipper MJ; Cuneo KC; Owen D; Lawrence TS
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):212-219. PubMed ID: 32853708
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
10. The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy.
Jackson WC; Hartman HE; Gharzai LA; Maurino C; Karnak DM; Mendiratta-Lala M; Parikh ND; Mayo CS; Haken RKT; Schipper MJ; Cuneo KC; Lawrence TS
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):127-134. PubMed ID: 33878421
[TBL] [Abstract][Full Text] [Related]
11. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.
Jun BG; Kim YD; Cheon GJ; Kim ES; Jwa E; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Lee SH; Kim HS
Korean J Intern Med; 2018 Nov; 33(6):1093-1102. PubMed ID: 28844122
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration.
Lee S; Kim H; Ji Y; Cho B; Kim SS; Jung J; Kwak J; Park JH; Lee SW; Kim JH; Yoon SM
Sci Rep; 2018 Nov; 8(1):16224. PubMed ID: 30385839
[TBL] [Abstract][Full Text] [Related]
15. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
[TBL] [Abstract][Full Text] [Related]
16. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy.
Moon DH; Wang AZ; Tepper JE
Radiother Oncol; 2018 Mar; 126(3):527-533. PubMed ID: 29366521
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
[TBL] [Abstract][Full Text] [Related]
20. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Rim CH; Kim HJ; Seong J
Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
